 | • レポートコード：MRC2312MG09436 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、63ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の最小残存病変（MRD）検査市場規模と予測を収録しています。・世界の最小残存病変（MRD）検査市場：売上、2018年-2023年、2024年-2029年 ・世界の最小残存病変（MRD）検査市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の最小残存病変（MRD）検査市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「フローサイトメトリー」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 最小残存病変（MRD）検査のグローバル主要企業は、Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratoriesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、最小残存病変（MRD）検査のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の最小残存病変（MRD）検査市場：タイプ別、2018年-2023年、2024年-2029年 世界の最小残存病変（MRD）検査市場：タイプ別市場シェア、2022年 ・フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー 世界の最小残存病変（MRD）検査市場：用途別、2018年-2023年、2024年-2029年 世界の最小残存病変（MRD）検査市場：用途別市場シェア、2022年 ・専門診療所、病院、研究機関 世界の最小残存病変（MRD）検査市場：地域・国別、2018年-2023年、2024年-2029年 世界の最小残存病変（MRD）検査市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における最小残存病変（MRD）検査のグローバル売上、2018年-2023年 ・主要企業における最小残存病変（MRD）検査のグローバル売上シェア、2022年 ・主要企業における最小残存病変（MRD）検査のグローバル販売量、2018年-2023年 ・主要企業における最小残存病変（MRD）検査のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratories ************************************************************* ・調査・分析レポートの概要 最小残存病変（MRD）検査市場の定義 市場セグメント 世界の最小残存病変（MRD）検査市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の最小残存病変（MRD）検査市場規模 世界の最小残存病変（MRD）検査市場規模：2022年 VS 2029年 世界の最小残存病変（MRD）検査市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの最小残存病変（MRD）検査の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の最小残存病変（MRD）検査製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー 最小残存病変（MRD）検査のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：専門診療所、病院、研究機関 最小残存病変（MRD）検査の用途別グローバル売上・予測 ・地域別市場分析 地域別最小残存病変（MRD）検査市場規模 2022年と2029年 地域別最小残存病変（MRD）検査売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratories ... |
This research report provides a comprehensive analysis of the Minimal Residual Disease (MRD) Testing market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Minimal Residual Disease (MRD) Testing market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Minimal Residual Disease (MRD) Testing, challenges faced by the industry, and potential opportunities for market players.
The global Minimal Residual Disease (MRD) Testing market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Minimal Residual Disease (MRD) Testing market presents opportunities for various stakeholders, including Specialty Clinics, Hospitals. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Minimal Residual Disease (MRD) Testing market. Additionally, the growing consumer demand present avenues for market expansion.
The global Minimal Residual Disease (MRD) Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Minimal Residual Disease (MRD) Testing market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Minimal Residual Disease (MRD) Testing market.
Market Overview: The report provides a comprehensive overview of the Minimal Residual Disease (MRD) Testing market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Flow Cytometry, Polymerase Chain Reaction), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Minimal Residual Disease (MRD) Testing market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Minimal Residual Disease (MRD) Testing market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Minimal Residual Disease (MRD) Testing market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Minimal Residual Disease (MRD) Testing market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Minimal Residual Disease (MRD) Testing market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Minimal Residual Disease (MRD) Testing market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Minimal Residual Disease (MRD) Testing, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Minimal Residual Disease (MRD) Testing market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Minimal Residual Disease (MRD) Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Flow Cytometry
Polymerase Chain Reaction
Next-generation Sequencing
Liquid Biopsies
Market segment by Application
Specialty Clinics
Hospitals
Research Institutions
Global Minimal Residual Disease (MRD) Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sysmex Corporation
Natera
Asuragen
Quest Diagnostics
Mission Bio
LabCorp
Guardant Health
NeoGenomics Laboratories
ARUP Laboratories
NeoGenomics , Inc
Opko Health
Bio-Rad Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Minimal Residual Disease (MRD) Testing, market overview.
Chapter 2: Global Minimal Residual Disease (MRD) Testing market size in revenue.
Chapter 3: Detailed analysis of Minimal Residual Disease (MRD) Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Minimal Residual Disease (MRD) Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Minimal Residual Disease (MRD) Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Minimal Residual Disease (MRD) Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Minimal Residual Disease (MRD) Testing Overall Market Size
2.1 Global Minimal Residual Disease (MRD) Testing Market Size: 2022 VS 2029
2.2 Global Minimal Residual Disease (MRD) Testing Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Minimal Residual Disease (MRD) Testing Players in Global Market
3.2 Top Global Minimal Residual Disease (MRD) Testing Companies Ranked by Revenue
3.3 Global Minimal Residual Disease (MRD) Testing Revenue by Companies
3.4 Top 3 and Top 5 Minimal Residual Disease (MRD) Testing Companies in Global Market, by Revenue in 2022
3.5 Global Companies Minimal Residual Disease (MRD) Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Minimal Residual Disease (MRD) Testing Players in Global Market
3.6.1 List of Global Tier 1 Minimal Residual Disease (MRD) Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 Minimal Residual Disease (MRD) Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Minimal Residual Disease (MRD) Testing Market Size Markets, 2022 & 2029
4.1.2 Flow Cytometry
4.1.3 Polymerase Chain Reaction
4.1.4 Next-generation Sequencing
4.1.5 Liquid Biopsies
4.2 By Type – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
4.2.1 By Type – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
4.2.2 By Type – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
4.2.3 By Type – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Minimal Residual Disease (MRD) Testing Market Size, 2022 & 2029
5.1.2 Specialty Clinics
5.1.3 Hospitals
5.1.4 Research Institutions
5.2 By Application – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
5.2.1 By Application – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
5.2.2 By Application – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
5.2.3 By Application – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Minimal Residual Disease (MRD) Testing Market Size, 2022 & 2029
6.2 By Region – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
6.2.1 By Region – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
6.2.2 By Region – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
6.2.3 By Region – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.3.2 US Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.3.3 Canada Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.3.4 Mexico Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.4.2 Germany Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.3 France Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.4 U.K. Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.5 Italy Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.6 Russia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.7 Nordic Countries Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.8 Benelux Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.5.2 China Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.3 Japan Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.4 South Korea Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.5 Southeast Asia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.6 India Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.6.2 Brazil Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.6.3 Argentina Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.7.2 Turkey Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.3 Israel Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.4 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.5 UAE Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
7 Minimal Residual Disease (MRD) Testing Companies Profiles
7.1 Sysmex Corporation
7.1.1 Sysmex Corporation Company Summary
7.1.2 Sysmex Corporation Business Overview
7.1.3 Sysmex Corporation Minimal Residual Disease (MRD) Testing Major Product Offerings
7.1.4 Sysmex Corporation Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.1.5 Sysmex Corporation Key News & Latest Developments
7.2 Natera
7.2.1 Natera Company Summary
7.2.2 Natera Business Overview
7.2.3 Natera Minimal Residual Disease (MRD) Testing Major Product Offerings
7.2.4 Natera Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.2.5 Natera Key News & Latest Developments
7.3 Asuragen
7.3.1 Asuragen Company Summary
7.3.2 Asuragen Business Overview
7.3.3 Asuragen Minimal Residual Disease (MRD) Testing Major Product Offerings
7.3.4 Asuragen Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.3.5 Asuragen Key News & Latest Developments
7.4 Quest Diagnostics
7.4.1 Quest Diagnostics Company Summary
7.4.2 Quest Diagnostics Business Overview
7.4.3 Quest Diagnostics Minimal Residual Disease (MRD) Testing Major Product Offerings
7.4.4 Quest Diagnostics Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.4.5 Quest Diagnostics Key News & Latest Developments
7.5 Mission Bio
7.5.1 Mission Bio Company Summary
7.5.2 Mission Bio Business Overview
7.5.3 Mission Bio Minimal Residual Disease (MRD) Testing Major Product Offerings
7.5.4 Mission Bio Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.5.5 Mission Bio Key News & Latest Developments
7.6 LabCorp
7.6.1 LabCorp Company Summary
7.6.2 LabCorp Business Overview
7.6.3 LabCorp Minimal Residual Disease (MRD) Testing Major Product Offerings
7.6.4 LabCorp Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.6.5 LabCorp Key News & Latest Developments
7.7 Guardant Health
7.7.1 Guardant Health Company Summary
7.7.2 Guardant Health Business Overview
7.7.3 Guardant Health Minimal Residual Disease (MRD) Testing Major Product Offerings
7.7.4 Guardant Health Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.7.5 Guardant Health Key News & Latest Developments
7.8 NeoGenomics Laboratories
7.8.1 NeoGenomics Laboratories Company Summary
7.8.2 NeoGenomics Laboratories Business Overview
7.8.3 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.8.4 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.8.5 NeoGenomics Laboratories Key News & Latest Developments
7.9 ARUP Laboratories
7.9.1 ARUP Laboratories Company Summary
7.9.2 ARUP Laboratories Business Overview
7.9.3 ARUP Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.9.4 ARUP Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.9.5 ARUP Laboratories Key News & Latest Developments
7.10 NeoGenomics , Inc
7.10.1 NeoGenomics , Inc Company Summary
7.10.2 NeoGenomics , Inc Business Overview
7.10.3 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Major Product Offerings
7.10.4 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.10.5 NeoGenomics , Inc Key News & Latest Developments
7.11 Opko Health
7.11.1 Opko Health Company Summary
7.11.2 Opko Health Business Overview
7.11.3 Opko Health Minimal Residual Disease (MRD) Testing Major Product Offerings
7.11.4 Opko Health Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.11.5 Opko Health Key News & Latest Developments
7.12 Bio-Rad Laboratories
7.12.1 Bio-Rad Laboratories Company Summary
7.12.2 Bio-Rad Laboratories Business Overview
7.12.3 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.12.4 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.12.5 Bio-Rad Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer